231 related articles for article (PubMed ID: 22836046)
1. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Chen J; Shi J; Xie WF; Zeng X; Lin Y
Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
3. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
[TBL] [Abstract][Full Text] [Related]
6. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
7. Aminoadamantanes for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
9. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
[TBL] [Abstract][Full Text] [Related]
10. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072
[TBL] [Abstract][Full Text] [Related]
11. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.
Hartwell D; Shepherd J
Int J Technol Assess Health Care; 2009 Jan; 25(1):56-62. PubMed ID: 19126252
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
14. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
[TBL] [Abstract][Full Text] [Related]
16. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
Shire NJ; Welge JA; Sherman KE
J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715
[TBL] [Abstract][Full Text] [Related]
17. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
20. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
Fabrizi F; Dixit V; Martin P; Messa P
J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]